for people ages 18-70 (full criteria)
at Kirkland, Washington and other locations
study started
estimated completion



This is a multicenter, open-label extension (OLE) study of ADS-5102 (amantadine extended release [ER] capsules) in subjects with MS and walking impairment who completed a prior study of ADS-5102 in subjects with MS.

Official Title

A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment


Multiple Sclerosis Walking Impairment Sclerosis Amantadine ADS-5102


You can join if…

Open to people ages 18-70

  • Signed a current IRB-approved informed consent form
  • Successful completion of a prior double blind study of ADS-5102 in patients with MS walking impairment.

You CAN'T join if...

  • Based on the judgment of the investigator or Medical Monitor, participation in the study would jeopardize the safety of the subject.
  • If female, is pregnant or lactating
  • If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize a highly effective hormonal method of contraception (an IUD, or vasectomized male partner is also acceptable), in combination with a barrier method, from baseline through at least 4 weeks after the completion of study treatment. If a sexually active male, does not agree to utilize condoms from screening through at least 4 weeks after the completion of study treatment.
  • Anticipated treatment with any amantadine formulation other than ADS-5102
  • Planned participation in another interventional clinical trial


  • Adamas Clinical Site accepting new patients
    Kirkland Washington 98034 United States
  • Adamas Clinical Site accepting new patients
    Fort Collins Colorado 80528 United States


accepting new patients
Start Date
Completion Date
Adamas Pharmaceuticals, Inc.
Sign up for this study
Phase 3
Study Type
Last Updated